Healthcare Realty Trust (HR) Q2 2026 Earnings Call Transcript

Healthcare Realty Trust reported Q2 normalized FFO of $0.41/share and 5.1% same-store cash NOI growth, driven by 88.5% tenant retention and 4.8% cash leasing spreads (3% average annual escalators). Management raised full-year normalized FFO guidance to $1.64–$1.66/share (midpoint +$0.02) and same-store cash NOI growth guidance to 4.25%–5.0% (bottom +50 bps), supported by improving occupancy (92.7%) and 350k sq ft new leasing. Capital allocation strengthened via $200m of JV acquisition assets (7.5% cash yield vs ~6% implied cap rate), $175m total share repurchases since the strategic plan, and refinancing steps (3% $700m exchangeable notes used to repay $600m 3.5% notes due Aug 2026).

Analysis

Near term, this reads as a quality-upgrade story more than a simple earnings beat. The real mechanism is that HR is converting an under-earning portfolio into a compounding machine: higher occupancy, lower re-tenanting friction, and more 3% escalators create a cleaner FFO path, while redevelopments and JV acquisitions add incremental spread without forcing balance-sheet strain. Second-order winners are KKR as the capital partner and service/capex vendors tied to campus redevelopments; the relative losers are medical office peers with weaker internal growth engines and less direct health-system access.

Over the next 1-3 months, the key catalyst is execution conversion: SNO units, the Nashville lease rollout, and whether the guidance raise keeps getting credibility in a market that usually discounts REIT “story” upgrades. The main risk is that the easy occupancy comp rolls off just as rent growth has to carry the baton; if same-store cash NOI stalls below the mid-4% area, the stock will likely de-rate back to a standard MOB multiple. A second risk is rate beta: higher long-end yields would compress cap rates and make the accretive spread on acquisitions/redevelopment look less attractive.

Contrarian view: consensus may be too focused on headline growth and not enough on durability. A lot of the upside is coming from portfolio repair and balance-sheet cleanup, which is real but not infinitely repeatable; once leverage normalizes and occupancy nears a ceiling, the market will demand proof that the 4%-plus growth can persist without more asset sales or equity. The thesis is falsified if 10-year yields back up meaningfully and HR cannot keep guidance rising, or if occupancy/retention stalls despite the current leasing pipeline.

Key Decisions for Investors

• Long HR on any post-earnings fade over the next 1-2 weeks; this is a cleaner internal-growth REIT than the market is likely to price at first blush. Target: hold 3-6 months for SNO conversion and leasing-spread follow-through; invalidate if same-store NOI guidance slips back toward 4%.
• Pair trade: long HR / short DOC for 6-12 months. HR has better visible organic growth, stronger capital-allocation optionality, and less reliance on external capital markets; DOC remains more exposed to multiple compression if rates back up.
• Use a 3-6 month HR call spread instead of outright equity if implied vol stays reasonable. Structure it to express upside from guidance credibility while limiting downside if the market views the quarter as already priced in.
• Watch-list alert: if the 10-year Treasury rises sharply or MOB cap rates begin widening, trim HR into strength. That is the clearest falsifier for the accretion math on JV acquisitions and redevelopment yields.